|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SFXN4 |
Gene summary for SFXN4 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SFXN4 | Gene ID | 119559 |
| Gene name | sideroflexin 4 | |
| Gene Alias | BCRM1 | |
| Cytomap | 10q26.11 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q6P4A7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 119559 | SFXN4 | HTA11_347_2000001011 | Human | Colorectum | AD | 2.11e-07 | 3.95e-01 | -0.1954 |
| 119559 | SFXN4 | HTA11_866_2000001011 | Human | Colorectum | AD | 9.53e-04 | 2.38e-01 | -0.1001 |
| 119559 | SFXN4 | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.78e-05 | 2.88e-01 | 0.0674 |
| 119559 | SFXN4 | HTA11_7469_2000001011 | Human | Colorectum | AD | 3.33e-03 | 7.33e-01 | -0.0124 |
| 119559 | SFXN4 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 5.79e-09 | 5.40e-01 | 0.3859 |
| 119559 | SFXN4 | A015-C-203 | Human | Colorectum | FAP | 1.48e-05 | -1.76e-01 | -0.1294 |
| 119559 | SFXN4 | A002-C-205 | Human | Colorectum | FAP | 9.51e-05 | -2.00e-01 | -0.1236 |
| 119559 | SFXN4 | A015-C-006 | Human | Colorectum | FAP | 4.23e-02 | -1.63e-01 | -0.0994 |
| 119559 | SFXN4 | A015-C-106 | Human | Colorectum | FAP | 2.81e-02 | -1.24e-01 | -0.0511 |
| 119559 | SFXN4 | A015-C-104 | Human | Colorectum | FAP | 3.12e-04 | -1.84e-01 | -0.1899 |
| 119559 | SFXN4 | A002-C-116 | Human | Colorectum | FAP | 1.50e-03 | -1.04e-01 | -0.0452 |
| 119559 | SFXN4 | A018-E-020 | Human | Colorectum | FAP | 7.11e-03 | -1.48e-01 | -0.2034 |
| 119559 | SFXN4 | LZE2T | Human | Esophagus | ESCC | 1.79e-04 | 6.29e-01 | 0.082 |
| 119559 | SFXN4 | LZE4T | Human | Esophagus | ESCC | 6.88e-07 | 2.33e-01 | 0.0811 |
| 119559 | SFXN4 | LZE24T | Human | Esophagus | ESCC | 4.83e-24 | 6.23e-01 | 0.0596 |
| 119559 | SFXN4 | LZE6T | Human | Esophagus | ESCC | 6.96e-05 | 2.88e-01 | 0.0845 |
| 119559 | SFXN4 | P1T-E | Human | Esophagus | ESCC | 6.88e-05 | 3.65e-01 | 0.0875 |
| 119559 | SFXN4 | P2T-E | Human | Esophagus | ESCC | 2.10e-23 | 4.73e-01 | 0.1177 |
| 119559 | SFXN4 | P4T-E | Human | Esophagus | ESCC | 4.59e-25 | 6.44e-01 | 0.1323 |
| 119559 | SFXN4 | P5T-E | Human | Esophagus | ESCC | 1.21e-22 | 5.37e-01 | 0.1327 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0006839 | Colorectum | AD | mitochondrial transport | 102/3918 | 254/18723 | 1.87e-12 | 3.08e-10 | 102 |
| GO:1990542 | Colorectum | AD | mitochondrial transmembrane transport | 47/3918 | 102/18723 | 1.09e-08 | 6.52e-07 | 47 |
| GO:00068392 | Colorectum | MSS | mitochondrial transport | 93/3467 | 254/18723 | 6.14e-12 | 9.82e-10 | 93 |
| GO:19905422 | Colorectum | MSS | mitochondrial transmembrane transport | 41/3467 | 102/18723 | 2.70e-07 | 1.11e-05 | 41 |
| GO:19905423 | Colorectum | FAP | mitochondrial transmembrane transport | 29/2622 | 102/18723 | 1.09e-04 | 1.80e-03 | 29 |
| GO:00068394 | Colorectum | FAP | mitochondrial transport | 55/2622 | 254/18723 | 5.58e-04 | 6.24e-03 | 55 |
| GO:0006839110 | Esophagus | ESCC | mitochondrial transport | 187/8552 | 254/18723 | 8.35e-20 | 9.81e-18 | 187 |
| GO:1990542110 | Esophagus | ESCC | mitochondrial transmembrane transport | 72/8552 | 102/18723 | 2.94e-07 | 4.23e-06 | 72 |
| GO:000683912 | Liver | HCC | mitochondrial transport | 184/7958 | 254/18723 | 2.30e-22 | 3.83e-20 | 184 |
| GO:199054212 | Liver | HCC | mitochondrial transmembrane transport | 78/7958 | 102/18723 | 2.73e-12 | 1.26e-10 | 78 |
| GO:000683918 | Oral cavity | OSCC | mitochondrial transport | 162/7305 | 254/18723 | 8.96e-16 | 6.52e-14 | 162 |
| GO:199054218 | Oral cavity | OSCC | mitochondrial transmembrane transport | 56/7305 | 102/18723 | 8.06e-04 | 4.32e-03 | 56 |
| GO:000683919 | Oral cavity | LP | mitochondrial transport | 119/4623 | 254/18723 | 1.06e-14 | 1.33e-12 | 119 |
| GO:199054219 | Oral cavity | LP | mitochondrial transmembrane transport | 37/4623 | 102/18723 | 5.93e-03 | 3.53e-02 | 37 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SFXN4 | SNV | Missense_Mutation | rs751311051 | c.239N>T | p.Ser80Leu | p.S80L | Q6P4A7 | protein_coding | tolerated(1) | benign(0.001) | TCGA-GM-A3XN-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | CR |
| SFXN4 | insertion | In_Frame_Ins | novel | c.365_366insGGGGAGATGTTGGCGTCAGACAAGCCTGGGCCCTCATCC | p.Phe122delinsLeuGlyArgCysTrpArgGlnThrSerLeuGlyProHisPro | p.F122delinsLGRCWRQTSLGPHP | Q6P4A7 | protein_coding | TCGA-A2-A0CP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| SFXN4 | SNV | Missense_Mutation | c.306N>A | p.Asn102Lys | p.N102K | Q6P4A7 | protein_coding | tolerated(1) | benign(0.006) | TCGA-EK-A3GJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| SFXN4 | SNV | Missense_Mutation | c.275G>C | p.Ser92Thr | p.S92T | Q6P4A7 | protein_coding | deleterious(0.05) | benign(0.322) | TCGA-AA-3673-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| SFXN4 | SNV | Missense_Mutation | novel | c.776C>G | p.Thr259Ser | p.T259S | Q6P4A7 | protein_coding | tolerated(0.07) | benign(0.259) | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SFXN4 | SNV | Missense_Mutation | novel | c.491G>A | p.Arg164Lys | p.R164K | Q6P4A7 | protein_coding | tolerated(1) | benign(0.137) | TCGA-AA-A029-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| SFXN4 | SNV | Missense_Mutation | c.335C>A | p.Ala112Glu | p.A112E | Q6P4A7 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD | |
| SFXN4 | SNV | Missense_Mutation | rs747282264 | c.746C>T | p.Thr249Met | p.T249M | Q6P4A7 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| SFXN4 | SNV | Missense_Mutation | novel | c.790N>A | p.Pro264Thr | p.P264T | Q6P4A7 | protein_coding | tolerated(0.07) | probably_damaging(0.997) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SFXN4 | SNV | Missense_Mutation | rs368065380 | c.377N>T | p.Thr126Met | p.T126M | Q6P4A7 | protein_coding | tolerated(0.7) | benign(0) | TCGA-AJ-A3OK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | CR |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |